Worth reading
43Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
135
¥100 millionWording
Conditional
How definitive the wording is.This transaction
Transfer of the Japanese Marketing Authorization for YURIS Tablets (dotinurad) and Acquisition of Related AssetsCounterpartyFuji Yakuhin Co., Ltd.
Disclosing companyMochida Pharmaceutical Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Net SalesApproximately ¥4.6 billion (fiscal year ended March 2025)
Consideration and expenses
Acquisition price¥13.5 billion
Impact on Business Performance
There will be no impact on consolidated results for the fiscal year ending March 2026. The consolidated earnings forecast for the fiscal year ending March 2027 will be disclosed when the results for the fiscal year ending March 2026 are announced, scheduled for May 2026.
Procedures and assumptions
Conditions Precedent to ExecutionThe transfer of the marketing authorization is scheduled to be completed after the necessary procedures with the Ministry of Health, Labour and Welfare and other authorities.
Management structure after acquisitionMochida Pharmaceutical Co., Ltd. will become the marketing authorization holder for the product and will continue sales and information-provision activities. Under a contract manufacturing agreement, Fuji Yakuhin Co., Ltd. will continue to manufacture the product and supply it to Mochida Pharmaceutical Co., Ltd.
| Item | Details |
|---|---|
| Transaction name | Transfer of the Japanese Marketing Authorization for YURIS Tablets (dotinurad) and Acquisition of Related Assets |
| Counterparty name | Fuji Yakuhin Co., Ltd. |
| Net Sales of the Subject Company | Approximately ¥4.6 billion (fiscal year ended March 2025) |
| Acquisition price | ¥13.5 billion |
| Impact on Business Performance | There will be no impact on consolidated results for the fiscal year ending March 2026. The consolidated earnings forecast for the fiscal year ending March 2027 will be disclosed when the results for the fiscal year ending March 2026 are announced, scheduled for May 2026. |
| Date of board resolution | 30 March 2026 |
| Contract Date | 30 March 2026 |
| Execution Date / Effective Date | 30 June 2026 (scheduled) |
| Conditions Precedent to Execution | The transfer of the marketing authorization is scheduled to be completed after the necessary procedures with the Ministry of Health, Labour and Welfare and other authorities. |
| Management structure after acquisition | Mochida Pharmaceutical Co., Ltd. will become the marketing authorization holder for the product and will continue sales and information-provision activities. Under a contract manufacturing agreement, Fuji Yakuhin Co., Ltd. will continue to manufacture the product and supply it to Mochida Pharmaceutical Co., Ltd. |
Items this document does not state (22)
Name of the Subject CompanyBusiness Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Mochida Pharmaceutical Co., Ltd. determined that having the marketing authorization for YURIS Tablets (dotinurad) change from Fuji Yakuhin Co., Ltd. to Mochida Pharmaceutical Co., Ltd. was the best way to continue providing the product to patients and contributing to healthcare.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.